News coverage about Hill-Rom (NYSE:HRC) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Hill-Rom earned a coverage optimism score of 0.24 on Accern’s scale. Accern also gave news headlines about the medical technology company an impact score of 47.1366954586226 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several brokerages have recently issued reports on HRC. Barclays reaffirmed a “buy” rating and set a $100.00 price target on shares of Hill-Rom in a research note on Wednesday, January 10th. Morgan Stanley lowered Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. KeyCorp reiterated a “buy” rating and issued a $94.00 price objective on shares of Hill-Rom in a report on Thursday, December 21st. Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a report on Thursday, January 18th. Finally, Bank of America reiterated a “hold” rating on shares of Hill-Rom in a report on Wednesday, November 22nd. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $95.38.
Hill-Rom stock traded down $0.43 during mid-day trading on Thursday, hitting $85.28. The stock had a trading volume of 89,571 shares, compared to its average volume of 531,443. The company has a quick ratio of 1.29, a current ratio of 1.75 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $5,769.03, a PE ratio of 29.22, a P/E/G ratio of 1.40 and a beta of 1.03. Hill-Rom has a 52 week low of $68.95 and a 52 week high of $91.11.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 23rd will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, March 22nd. This is a boost from Hill-Rom’s previous quarterly dividend of $0.18. This represents a $0.80 annualized dividend and a yield of 0.94%. Hill-Rom’s dividend payout ratio is 24.49%.
Hill-Rom Holdings, Inc is a global medical technology company. The Company partners with health care providers across care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: advancing mobility, wound care and prevention, patient monitoring and diagnostics, surgical safety and efficiency and respiratory health.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.